Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bococizumab in Asian Subjects with Hyperlipidemia
NCT02947334Phase 3Withdrawn
- Sponsor
- Pfizer
- Start
- Oct 2016
- Primary completion
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary hyperlipidemia and mixed dyslipidemia comparing Bococizumab with Placebo (2 arms). Primary endpoint: Percent change from baseline in fasting LDL-C at 12 weeks. Planned start Oct 2016; status: withdrawn.
02
Drugs
bococizumab
03
Conditions
primary hyperlipidemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT02947334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947334.